Finasteride and High-Grade Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Finasteride and high-grade prostate cancer.
To the Editor: In the Prostate Cancer Prevention Trial, an increased rate of high-grade cancer was observed in the finasteride group (1). The recently published analysis by Redman et al. (2) suggests that this observation was the result of detection bias rather than a true increase. However, the marked increase in the estimated rate of high-grade cancer in the placebo group calls into question ...
متن کاملFinasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
BACKGROUND The Prostate Cancer Prevention Trial (PCPT) reported a decreased incidence of prostate cancer overall but an increase in the incidence of high-grade prostate cancer with finasteride compared with placebo. We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size....
متن کاملGrade-dependent Response to Finasteride in Early Prostate Cancer
a Veterans Affairs Medical Center, 1201 N.W. 16th Street, Miami, FL 33125, USA b Department of Urology, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th St, Miami, FL 33199, USA c Divisions of Hematology/Oncology and Endocrinology, Department of Medicine, University of Miami, Miller School of Medicine, 1800 N.W. 10th Ave, Miami, FL 33126, USA d Department of ...
متن کاملFinasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
Finasteride taken for 7 years in the Prostate Cancer Prevention Trial (PCPT) reduced the risk of prostate cancer by 25%, but with an apparent increased risk of high-grade disease. Subsequent analyses found that finasteride biases toward improved prostate cancer detection and accuracy in prostate cancer grading at biopsy. In our first analysis of the present study, we accounted for these biases ...
متن کاملHigh-grade prostate cancer and the prostate cancer prevention trial.
Prostate cancer remains a major public health challenge worldwide and has defied efforts to develop effective and acceptable therapy for its control. This reality provides a strong rationale for focusing on prevention. In the Prostate Cancer Prevention Trial (PCPT), the 5α-reductase inhibitor finasteride reduced the prevalence of prostate cancer by 24.8% (versus placebo) in 18,882 men randomize...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Prevention Research
سال: 2009
ISSN: 1940-6207,1940-6215
DOI: 10.1158/1940-6207.capr-08-0117